The titers of anti-PAD4 autoantibodies were previously analyzed cross-sectionally in non-African populations [6, 8, 9], and studies have determined the prevalence of anti-PAD4 antibodies in established RA to be between 35 and 45 % [7, 10–12]. Here, PADI4 is linked to rheumatoid arthritis.